CAEL-101 for AL Amyloidosis
Study Summary
This trial is testing a drug to see if it can improve overall survival for people with stage IIIa AL amyloidosis, a disease where abnormal proteins build up in organs.
- AL Amyloidosis
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Are there other similar testing procedures for CAEL-101?
"Right now, there are over 1300 trials researching CAEL-101 with almost 300 of those in Phase 3. Most of the testing for CAEL-101 is happening in Philadelphia, but there are 43000+ locations running studies related to CAEL-101."
Does this trial have a lot of locations in North America?
"67 medical centres across the United States are participating in this clinical trial, including renowned institutions such as Indiana University School of Medicine Amyloid Research and Treatment, Medical College of Wisconsin, and Memorial Sloan Kettering Cancer Center."
What are the conditions that CAEL-101 is designed to address?
"Oftentimes, CAEL-101 is used to ameliorate synovitis. Additionally, it has shown efficacy in treating ophthalmia, cancerous growths in the lungs, and branch retinal vein occlusion."
Has CAEL-101 received permission from the FDA to be used?
"CAEL-101 is safe according to our team's estimation. This is a Phase 3 trial, which means that efficacy has been supported by some data and safety has multiple rounds of supportive data."